ABSTRACT OBJECTIVES This study sought to assess the clinical efficacy, safety, and clinical utility of a novel electroanatomical mapping system. BACKGROUND A new mapping system capable of rapidly acquiring detailed maps based on automatic annotation of
date there is no report of the utility of this system in humans. This paper describes the initial experience using the Rhythmia system and the mini-basket catheter, focusing on the safety, feasibility, and efficacy in mapping the atria and left ventricle (LV) in humans.
METHODS

PATIENTS.
We studied the first 20 consecutive electrophysiological procedures, using the Rhythmia mapping system at our institution during the first 3 months the system and catheter were clinically available. A detailed description of the cases is shown in Table 1 .
All patients were adults (39 to 85 years of age), 7 patients had structurally normal hearts, 9 patients had had heart failure, and 4 had adult congenital heart disease. Fourteen patients were admitted electively for procedures, and 6 patients required urgent ablation. Written informed consent was obtained in all cases according to standard practice. Patient and procedural data were prospectively collected. Mapping system and mini-basket multielectrode catheter.
The Rhythmia mapping system is a 3-dimensional (3D) electroanatomical mapping platform that uses a hybrid location technology that combines impedance and magnetic location. The magnetic field is generated by a localization generator positioned under the catheter laboratory table and is capable of locating the magnetically tracked catheters with an accuracy of #1 mm. The impedance location technology is used to track catheters that are not equipped with a magnetic sensor. The system then maps the impedance field measurements to the magnetic location coordinates and creates an impedance field map.
This map is used to enhance the accuracy of the impedance location. The Orion catheter is a bidirectional deflectable, multielectrode, mini-basket mapping catheter (Figure 1) . Its maximum shaft diameter is 8.5-F and is advanced into cardiac chambers by using 9-F sheaths. The catheter can acquire points at variable degrees of deployment from undeployed (3 mm) to fully deployed (22 mm).
M a p a c q u i s i t i o n . The Orion catheter was gently manipulated inside the chamber of interest and automatically acquired points with every accepted beat.
Criteria used for beat acceptance were: 1) a stable cycle length; 2) stable timing difference between 2 reference electrodes; 3) respiration gating; 4) stable catheter location; 5) stability of catheter signal compared to adjacent points; and 6) tracking quality. Mapping during AF was achieved by enabling only criteria c, d, and f. For mapping of VEs and VT, an additional criterion of correlation to a reference surface electrocardiogram (ECG) QRS interval morphology was applied.
T i m e a n d v o l t a g e m a p s . The setup for the mapping window was automatic. The system calculated the mean cycle length of the rhythm over 10 s and consequently set 100% of cycle length equally before and after the timing reference electrode (usually one of the coronary sinus [CS] electrograms, or the QRS interval of one of the surface ECG leads for ventricular rhythms). The final maps showed the activation propagation rather that the "early" and "late" points.
The mapping window could be moved at any time during or after the completion of the map by manually dragging its ends on the screen, using the pointing device (e.g., mouse), to focus on relevant parts of the cycle length, such as the diastolic part during VT, or to exclude nonrelevant electrograms such as the QRS interval during AT (Online Figure 1) .
For the bipolar time maps, the timing of the electrodes was based on the time difference between the maximum amplitude of the bipolar electrogram and the first reference electrode (timing reference). For electrograms with more than 1 potential, the system selected the potential that best matched the timing of the surrounding electrograms. For unipolar time maps, the timing was based on the most negative delta voltage/delta time (dV/dT) around the timing of the maximum bipolar signal. The bipolar and unipolar voltage maps were based on differences between the maximum and minimum peaks of the signal. Noise level and complete electrical silence were considered <0.03 mV, and low voltage areas were detected between 0.03 mV and 0.5 mV in the atria and 0.03 mV and 1.5 mV in the ventricles. 
Mantziari et al. 
RESULTS
We present data from the first 20 consecutive procedures ( Table 1) Figure 2B .
SAFETY. The mini-basket catheter was meticulously flushed and inserted to the cardiac chambers after an activated clotting time of $300 s was achieved and maintained with boluses of intravenous heparin Mantziari et al.
Clinical heart disease were studied, and gaps on previous lesions and/or atriotomy scars were identified as the isthmuses of slow conduction (Online Figure 3) , followed by successful ablation (no inducibility of tachycardias). In total, 9 macro-re-entry ATs were mapped. The system mapped 100% of cycle length of 8 ATs. In one case of short-lasting AT, the system was able to map 69% of the cycle length. VEs were mapped and ablated in 2 patients. In both cases, the system created a template to the clinical VE and could accurately identify the clinical VE, accept the relevant beat, and annotate the signal automatically (Online Figure 4 ).
Three patients with sustained monomorphic VT were studied (cases 16, 17, and 18). The LV was mapped using the transseptal (n ¼ 2) and transaortic (n ¼ 3) approaches. 
DISCUSSION
To our knowledge, this is the first description of the initial clinical experience of a novel rapid high-resolution mapping system in a variety of arrhythmias and substrates, Mantziari et al. We used the system in a variety of cardiac arrhythmias in order to explore its efficacy and potential future utility. In this initial experience, we observed that this system could accurately demonstrate gaps Mantziari et al.
Clinical Utility of Rapid High-Resolution Mapping
that the size and location of scar mapped on electroanatomical maps acquired with this system were highly correlated with scar observed in CMR (11).
However, looking further into scar at lower voltages may help to reveal channels of slow conduction and facilitate the substrate mapping and ablation of VT.
One unique characteristic of this mapping system was that we could easily change the mapping window retrospectively. By excluding the QRS interval and moving the window of interest on the diastolic part of the CL during VT enabled the mapping of the local activation along the critical isthmus of the VT that occurs during diastole (12, 13) . This feature requires further validation in a larger study.
The mean procedure duration and fluoroscopy time of the studies presented in this paper seems to be no shorter than usual for our institution (14) , but this is expected as we used the system to explore its potential and future clinical use and there was a learning curve for the operators and cardiac physiologists, therefore a direct comparison to previous standard clinical practice was not attempted.
STUDY LIMITATIONS. A small number of patients were included in this study, and a heterogeneous group of cases was described. A comparison to other mapping systems was not attempted at this stage due to catheter/system incompatibilities and to allow for a learning curve. The current report is a description of sequential cases rather than an experimental protocol, and on clinical grounds, there was no opportunity to map the RV in these cases, although we would anticipate very simple manipulation in the RV and its outflow tract based on experience in other chambers.
Similarly we did not use the system to perform epicardial mapping, where additional complexities may be encountered. We could not verify the accuracy of the voltage maps because no scar information from cardiac CMR was available. The system uses a hybrid magnetic and impedance location technology.
Although no discrepancy was noted between the system and the fluoroscopic location of the catheters, this has not been formally validated.
CONCLUSIONS
The novel rapid, automatic mapping system was used in a variety of human cardiac arrhythmias and proved to be both safe and efficacious. We were able to ac- 
